{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:10:18Z","timestamp":1780416618768,"version":"3.54.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100031961","name":"Funda\u00e7\u00e3o Edson Queiroz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031961","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.106972","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:39:11Z","timestamp":1767598751000},"page":"106972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neurological and paraclinical features differentiating Systemic lupus erythematosus, Sj\u00f6gren\u2019s disease, and neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1140-5991","authenticated-orcid":false,"given":"Ivna Lacerda Pereira","family":"N\u00f3brega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1511-9744","authenticated-orcid":false,"given":"Melissa Macedo Peixoto","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4489-3288","authenticated-orcid":false,"given":"Igor Bessa","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7957-0844","authenticated-orcid":false,"given":"Joz\u00e9lio Freire","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Sales Pitombeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1367-6782","authenticated-orcid":false,"given":"Carlos Ewerton Maia","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0001","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","article-title":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes","volume":"42","year":"1999","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0002","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/biom12040591","article-title":"Aquaporin-4 in neuromyelitis optica spectrum disorders: a target of autoimmunity in the central nervous system","volume":"12","author":"Abe","year":"2022","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0003","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/01658107.2017.1356856","article-title":"Diffusion-weighted imaging and post-contrast enhancement in differentiating optic neuritis and non-arteritic anterior optic neuropathy","volume":"42","author":"Adesina","year":"2017","journal-title":"Neuroophthalmology"},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0004","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3904\/kjim.2016.383","article-title":"Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus","volume":"34","author":"Ahn","year":"2019","journal-title":"Korean J. Intern. Med."},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.57.3.496","article-title":"The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus","volume":"57","author":"Ainiala","year":"2001","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2026.106972_bib0006","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","article-title":"Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder","volume":"94","author":"Aktas","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0007","article-title":"Neuromyelitis optica spectrum disorders in the Arabian Gulf: challenges and growing experience","volume":"6","author":"Alroughani","year":"2020","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0008","first-page":"192","article-title":"The kaleidoscope of neurological manifestations in primary Sj\u00f6gren\u2019s syndrome","volume":"37","author":"Alunno","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"issue":"10","key":"10.1016\/j.msard.2026.106972_bib0009","article-title":"An overview of systemic Lupus Erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1590\/S0034-72802012000200006","article-title":"Autoimmune optic neuropathy as the first manifestation of systemic lupus erythematosus","volume":"71","author":"Amigo","year":"2012","journal-title":"Rev. Bras. Oftalmol."},{"issue":"9","key":"10.1016\/j.msard.2026.106972_bib0011","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 EULAR\/ACR classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.msard.2026.106972_bib0012","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"12","key":"10.1016\/j.msard.2026.106972_bib0013","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1055\/s-0043-1777105","article-title":"Sjogren\u2019s syndrome: a neurological perspective","volume":"81","author":"Barsottini","year":"2023","journal-title":"Arq. Neuropsiquiatr."},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0014","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejrad.2009.09.029","article-title":"Imaging of the optic nerve","volume":"74","author":"Becker","year":"2010","journal-title":"Eur. J. Radiol."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/practneurol-2013-000651","article-title":"The neurology of Sjogren\u2019s syndrome and the rheumatology of peripheral neuropathy and myelitis","volume":"14","author":"Berkowitz","year":"2014","journal-title":"Pract. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0016","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41584-023-01057-6","article-title":"Epidemiology of Sj\u00f6gren syndrome","volume":"20","author":"Beydon","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.msard.2026.106972_bib0017","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/acr.23107","article-title":"Relationship between neuromyelitis optica spectrum disorder and Sj\u00f6gren\u2019s syndrome: central nervous system extraglandular disease or unrelated. Co-occurring autoimmunity?","volume":"69","author":"Birnbaum","year":"2017","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.msard.2026.106972_bib0018","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0019","first-page":"146","article-title":"Peripheral nervous system involvement in systemic lupus erythematosus: a review of the evidence","volume":"37","author":"Bortoluzzi","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.msard.2026.106972_bib0020","series-title":"Secretaria De Ci\u00eancia, Tecnologia e Inova\u00e7\u00e3o e Do Complexo Econ\u00f4mico-Industrial Da Sa\u00fade (SECTICS)","year":"2025"},{"key":"10.1016\/j.msard.2026.106972_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.47","article-title":"Sj\u00f6gren syndrome","volume":"2","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5","key":"10.1016\/j.msard.2026.106972_bib0022","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3390\/jcm9051482","article-title":"Clinical, radiological, and laboratory features of spinal cord involvement in primary Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Butryn","year":"2020","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102780","article-title":"Neuropsychiatric involvement in systemic lupus erythematosus: a review","volume":"20","author":"Carri\u00f3n-Barber\u00e0","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0024","doi-asserted-by":"crossref","first-page":"rkae031","DOI":"10.1093\/rap\/rkae031","article-title":"Area postrema syndrome secondary to primary Sjogren\u2019s syndrome","volume":"8","author":"Chen","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"issue":"10","key":"10.1016\/j.msard.2026.106972_bib0025","doi-asserted-by":"crossref","first-page":"e0059","DOI":"10.1097\/MD.0000000000010059","article-title":"A case report of neuromyelitis optica spectrum disorder with peripheral neuropathy as the first episode","volume":"97","author":"Chi","year":"2018","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0026","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cei.13630","article-title":"Magnetic resonance imaging in neuromyelitis optica spectrum disorder","volume":"206","author":"Clarke","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2026.106972_bib0027","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Contentti","year":"2021","journal-title":"J. Neuroinflammation"},{"issue":"8","key":"10.1016\/j.msard.2026.106972_bib0028","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.msard.2026.106972_bib0029","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/1744666X.2019.1564040","article-title":"Epidemiology, characterization and diagnosis of neuropsychiatric events in systemic lupus erythematosus","volume":"15","author":"de Amorim","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0031","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s42358-025-00438-7","article-title":"Recommendations on neurologic, cognitive, and psychiatric manifestations in patients with Sj\u00f6gren's disease by the Brazilian Society of Rheumatology","volume":"65","author":"de Oliveira","year":"2025","journal-title":"Adv. Rheumatol."},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0032","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/ijms21020650","article-title":"Mechanisms of disease in sj\u00f6gren syndrome\u2014new developments and directions","volume":"21","author":"de Paiva","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0033","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1590\/0004-282x20160193","article-title":"Neuromyelitis optica: phenotypic characteristics in a Brazilian case series","volume":"75","author":"Del Negro","year":"2017","journal-title":"Arq. Neuropsiquiatr."},{"issue":"5","key":"10.1016\/j.msard.2026.106972_bib0034","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.md.0000141099.53742.16","article-title":"Neurologic manifestations in primary Sj\u00f6gren syndrome: a study of 82 patients","volume":"83","author":"Delalande","year":"2004","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1148\/rg.2018170141","article-title":"Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis","volume":"38","author":"Dutra","year":"2018","journal-title":"Radiographics"},{"issue":"6","key":"10.1016\/j.msard.2026.106972_bib0036","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1177\/1352458511431727","article-title":"Comparison of clinical, immunological and neuroimaging features between anti-aquaporin-4 antibody-positive and antibody-negative Sjogren\u2019s syndrome patients with central nervous system manifestations","volume":"18","author":"Estiasari","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.106972_bib0037","article-title":"Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis","volume":"2015","author":"Etemadifar","year":"2015","journal-title":"Mult. Scler. Int."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0038","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0039","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-014-3066-3","article-title":"Neuromyelitis optica spectrum disorders associated with other autoimmune diseases","volume":"35","author":"Freitas","year":"2015","journal-title":"Rheumatol. Int."},{"issue":"11","key":"10.1016\/j.msard.2026.106972_bib0040","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1177\/0961203311403344","article-title":"Optic neuropathy as a presenting feature of systemic lupus erythematosus: two case reports and literature review","volume":"20","author":"Frigui","year":"2011","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0041","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12883-022-02621-5","article-title":"Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil","volume":"22","author":"Fukuda","year":"2022","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0042","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0043","first-page":"288","article-title":"Systemic Lupus Erythematosus Disease Activity Index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.msard.2026.106972_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117421","article-title":"Peripheral nervous system manifestations of reumatological diseases","volume":"424","author":"Gwathmey","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.106972_bib0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.41070","article-title":"Peripheral nervous system disease in systemic Lupus Erythematosus: results from an international inception cohort study","volume":"72","author":"Hanly","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0046","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00296-011-1824-z","article-title":"A case of primary Sj\u00f6gren\u2019s syndrome presenting primarily with central nervous system vasculitic involvement","volume":"32","author":"Hasiloglu","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"6","key":"10.1016\/j.msard.2026.106972_bib0047","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/ICU.0000000000000703","article-title":"Update on neuromyelitis optica spectrum disorder","volume":"31","author":"Holroyd","year":"2020","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.msard.2026.106972_bib0048","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.106972_bib0049","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1177\/09612033231185612","article-title":"Transverse myelitis associated with systemic lupus erythematosus (SLE-TM): a review article","volume":"32","author":"Jain","year":"2023","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primer"},{"issue":"8","key":"10.1016\/j.msard.2026.106972_bib0051","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1665","article-title":"Neuro-Sj\u00f6gren: uncommon or underestimated problem?","volume":"10","author":"Jask\u00f3lska","year":"2020","journal-title":"Brain Behav."},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0052","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13145","article-title":"Disease mechanisms in Sj\u00f6gren\u2019s syndrome: what do we know?","volume":"95","author":"Jonsson","year":"2022","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.msard.2026.106972_bib0053","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00234-001-0730-6","article-title":"Primary Sj\u00f6gren's syndrome initially manifested by optic neuritis: MRI findings","volume":"44","author":"Kadota","year":"2002","journal-title":"Neuroradiology"},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0054","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/13524585211024978","article-title":"Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder","volume":"28","author":"Kim","year":"2022","journal-title":"Mult Scler. J."},{"issue":"9","key":"10.1016\/j.msard.2026.106972_bib0055","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of Rituximab treatment in patients with Neuromyelitis Optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.106972_bib0056","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/acn3.51203","article-title":"Effect of plasma exchange in neuromyelitis optica spectrum disorder: a systematic reviewand meta-analysis","volume":"7","author":"Kosiyakul","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0057","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group(NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.106972_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104957","article-title":"Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis","volume":"79","author":"Lee","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2026.106972_bib0059","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41584-024-01163-z","article-title":"Recent advances in the diagnosis and management of neuropsychiatric lupus","volume":"20","author":"Legge","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"9451","key":"10.1016\/j.msard.2026.106972_bib0060","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0061","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"Palace J new therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.106972_bib0062","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/0961203314541690","article-title":"Myelitis in systemic lupus erythematosus frequently manifests as longitudinal and sometimes occurs at low disease activity","volume":"23","author":"Li","year":"2014","journal-title":"Lupus."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0063","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ene.15555","article-title":"Primary Sj\u00f6gren syndrome-related peripheral neuropathy: a systematic review and meta-analysis","volume":"30","author":"Liampas","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.106972_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.998328","article-title":"Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: a review","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"11","key":"10.1016\/j.msard.2026.106972_bib0065","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0066","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.rdc.2017.06.002","article-title":"Neurologic manifestations of primary SjOgren syndrome","volume":"43","author":"Margaretten","year":"2017","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.msard.2026.106972_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102364","article-title":"Sjogren's syndrome: old and new therapeutic targets","volume":"110","author":"Mavragani","year":"2020","journal-title":"J. Autoimmun"},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0068","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40674-017-0076-9","article-title":"Neurological complications of Sj\u00f6gren\u2019s syndrome: diagnosis and management","volume":"3","author":"McCoy","year":"2017","journal-title":"Curr. Treat. Options Rheumatol."},{"issue":"9","key":"10.1016\/j.msard.2026.106972_bib0069","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0070","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with Neuromyelitis Optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0071","first-page":"103","article-title":"Primary Sj\u00f6gren\u2019s syndrome: central and peripheral nervous system involvements","volume":"38l","author":"Mekinian","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0072","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1017\/S0317167100006697","article-title":"Primary Sj\u00f6gren\u2019s syndrome associated neuropathy","volume":"34","author":"Mellgren","year":"2007","journal-title":"Can. J. Neurol. Sci. J. Can. Sci. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0073","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000682","article-title":"Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus","volume":"32","author":"Moore","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0074","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/0961203314520843","article-title":"Neuropsychiatric systemic lupus erythematosus: association with global disease activity","volume":"23","author":"Morrison","year":"2014","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e40614","article-title":"Postrema area syndrome in the context of systemic lupus erythematosus: case report","volume":"11","author":"Mu\u00f1oz-Z\u00fa\u00f1iga","year":"2024","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0077","first-page":"807","article-title":"A case of systemic lupus erythematosus associated with cerebral arteritis: a case report and case-based literature review","volume":"82","author":"Nishigaichi","year":"2020","journal-title":"Nagoya J. Med. Sci."},{"key":"10.1016\/j.msard.2026.106972_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101430","article-title":"Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders","volume":"36","author":"Novi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0079","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1148\/rg.210045","article-title":"Central nervous system systemic lupus erythematosus: pathophysiologic, clinical, and imaging features","volume":"42","author":"Ota","year":"2022","journal-title":"Radiographics"},{"key":"10.1016\/j.msard.2026.106972_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577706","article-title":"Overcoming the challenges in diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay","volume":"360","author":"Pandit","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.106972_bib0081","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jns.2014.11.020","article-title":"Presence of anti-Ro\/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder","volume":"348","author":"Park","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"8","key":"10.1016\/j.msard.2026.106972_bib0082","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"4\u20135","key":"10.1016\/j.msard.2026.106972_bib0083","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.autrev.2014.01.009","article-title":"Diagnosis and classification of autoimmune optic neuropathy","volume":"13","author":"Petzold","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0084","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/157015911796557984","article-title":"Neuropsychiatric systemic lupus erythematosus","volume":"9","author":"Popescu","year":"2011","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2026.106972_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103716","article-title":"A point-of-care diagnostic test for aquaporin-4 antibody seropositive neuromyelitis optica","volume":"60","author":"Rice","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2026.106972_bib0087","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.106972_bib0088","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1007\/s00415-017-8519-7","article-title":"Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study","volume":"64","author":"Rivi\u00e8re","year":"2017","journal-title":"J. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2026.106972_bib0089","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1177\/0961203317694259","article-title":"Central nervous system vasculitis in systemic lupus erythematosus: a case series report in a tertiary referral centre","volume":"26","author":"Rodrigues","year":"2017","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.msard.2015.06.003","article-title":"Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: a meta-analysis","volume":"4","author":"Ruiz-Gaviria","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0091","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0961203314547795","article-title":"Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients","volume":"24","author":"Saison","year":"2015","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0092","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10067-023-06809-z","article-title":"Nationwide analysis of neuromyelitis optica in systemic lupus erythematosus and Sjogren\u2019s syndrome","volume":"43","author":"Sami","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.msard.2026.106972_bib0093","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0094","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 ACR-EULAR Classification criteria for primary Sj\u00f6gren\u2019s Syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol. Hoboken NJ"},{"issue":"17","key":"10.1016\/j.msard.2026.106972_bib0095","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","article-title":"Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG\u2013positive NMOSD","volume":"91","author":"Shosha","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2026.106972_bib0096","article-title":"Extensive longitudinal transverse myelitis in Systemic Lupus Erythematosus: presentation of a case and literature review","volume":"15","author":"Sierra-Merlano","year":"2023","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.msard.2026.106972_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103465","article-title":"A comprehensive review of the advances in neuromyelitis optica spectrum disorder","volume":"22","author":"Siriratnam","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.msard.2026.106972_bib0098","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1007\/s00415-020-10257-z","article-title":"Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis","volume":"268","author":"Siritho","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.106972_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2021.100320","article-title":"Cases of neuromyelitis optica spectrum disorder from the East Africa region, highlighting challenges in diagnostics and healthcare access","volume":"22","author":"Sokhi","year":"2021","journal-title":"eNeurologicalSci."},{"issue":"20","key":"10.1016\/j.msard.2026.106972_bib0100","first-page":"354","article-title":"The diagnosis and treatment of Sj\u00f6gren\u2019s syndrome","volume":"114","author":"Stefanski","year":"2017","journal-title":"Dtsch. Arztebl. Int."},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0101","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre,randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.106972_bib0102","doi-asserted-by":"crossref","first-page":"93","DOI":"10.55563\/clinexprheumatol\/jrz47c","article-title":"Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation","volume":"134","author":"Tani","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0103","doi-asserted-by":"crossref","first-page":"981","DOI":"10.18203\/2320-6012.ijrms20240552","article-title":"Area postrema syndrome: an atypical presentation of primary Sjogren's syndrome","volume":"12","author":"Tanwar","year":"2024","journal-title":"Int. J. Res. Med. Sci."},{"issue":"3","key":"10.1016\/j.msard.2026.106972_bib0104","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.msard.2026.106972_bib0105","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2214\/AJR.10.5984","article-title":"CNS involvement in primary Sj\u00f6gren syndrome: assessment of gray and white matter changes with MRI and voxel-based morphometry","volume":"197","author":"Tzarouchi","year":"2011","journal-title":"Am. J. Roentgenol."},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0106","first-page":"1","article-title":"A roadmap to increasing access to AQP4-ig testing for NMOSD: expert recommendations","volume":"83","author":"Vass\u00e3o-Araujo","year":"2025","journal-title":"Arq. Neuropsiquiatr."},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1756285611398702","article-title":"Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis","volume":"4","author":"Voss","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.msard.2026.106972_bib0108","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/10799893.2020.1830109","article-title":"Research and progress on biomarkers of neuromyelitis optica spectrum disorders","volume":"41","author":"Wang","year":"2021","journal-title":"J. Recept. Signal. Transduct."},{"key":"10.1016\/j.msard.2026.106972_bib0109","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221097330","article-title":"Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus","volume":"13","author":"Wang","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"9","key":"10.1016\/j.msard.2026.106972_bib0110","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicenter comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.msard.2026.106972_bib0111","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2026.106972_bib0112","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrumof neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.106972_bib0113","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2026.106972_bib0114","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult. Scler. J."},{"issue":"11\u201312","key":"10.1016\/j.msard.2026.106972_bib0115","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.106972_bib0116","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102421","article-title":"A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders","volume":"45","author":"Xie","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2026.106972_bib0117","first-page":"e4806","article-title":"Systemic Lupus erythematosus presenting as optic neuropathy: a case report","volume":"11","author":"Zahid","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.msard.2026.106972_bib0118","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1127417","article-title":"Pathogenesis and treatment of Sjogren\u2019s syndrome: review and update","volume":"14","author":"Zhan","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2026.106972_bib0119","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.106972_bib0120","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211054952","article-title":"Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levelsin neuromyelitis optica spectrum disorder","volume":"14","author":"Zhang","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.106972_bib0121","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.neurol.2020.07.019","article-title":"Area postrema syndrome as initial manifestation in neuromyelitis optica spectrum disorder patients: a retrospective study","volume":"177","author":"Zhou","year":"2021","journal-title":"Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:50:32Z","timestamp":1780415432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":121,"alternative-id":["S2211034826000088"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.106972","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurological and paraclinical features differentiating Systemic lupus erythematosus, Sj\u00f6gren\u2019s disease, and neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.106972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106972"}}